Lipum AB | MedPath

Lipum's SOL-116 Shows Promising Phase I Results for Rheumatoid Arthritis Treatment

a month ago

• Lipum has completed its Phase I clinical trial for SOL-116, demonstrating a favorable safety profile and predictable pharmacokinetics in both healthy volunteers and rheumatoid arthritis patients. • The drug candidate targets BSSL, a protein involved in inflammation, showing direct on-target activity with reduced BSSL levels in treated participants and minimal anti-drug antibody formation. • With backing from major shareholder Flerie AB, Lipum is now preparing to advance SOL-116 into Phase II clinical development, with GMP manufacturing already underway.

CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025

a month ago

• Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases. • AstraZeneca's portfolio saw substantial growth with expanded approvals for Imfinzi, Tagrisso, and Lynparza, strengthening partnerships with contract manufacturers including Lonza, Dottikon, and Samsung Biologics. • Contract manufacturers supporting treatments for autoimmune conditions showed strong performance, with Argenx's Vyvgart Hytrulo receiving expanded indications for myasthenia gravis and CIDP.